RARE — Ultragenyx Pharmaceutical Inc · catalysts, narrative & risks

Overview

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a rare-disease biopharmaceutical company headquartered in Novato, California, commercializing and developing therapies for ultra-rare genetic diseases across multiple modalities (biologics, small molecules, gene therapy, ASO) [24], [28]. As of mid-October 2026 the stock trades near its 52-week lows (~$14.50–14.89) after a sharp decline, and its market capitalization has compressed from roughly $2.5 billion in late August [5] to around $1.47 billion by mid-October [background]. Below I focus on the last ~1–3 months.

Recent catalysts (July–October 2026)